Unknown

Dataset Information

0

Predicting the Risk to Develop Preeclampsia in the First Trimester Combining Promoter Variant -98A/C of LGALS13 (Placental Protein 13), Black Ethnicity, Previous Preeclampsia, Obesity, and Maternal Age.


ABSTRACT: BACKGROUND:LGALS13 (placental protein 13 [PP13]) promoter DNA polymorphisms was evaluated in predicting preeclampsia (PE), given PP13's effects on hypotension, angiogenesis, and immune tolerance. METHODS:First-trimester plasma samples (49 term and 18 intermediate) of PE cases matched with 196 controls were collected from King's College Hospital, London, repository. Cell-free DNA was extracted and the LGALS13 exons were sequenced after PCR amplification. Expression of LGALS13 promoter reporter constructs was determined in BeWo trophoblast-like cells with luciferase assays. Adjusted odds ratio (OR) was calculated for the A/A genotype combined with maternal risk factors. RESULTS:The A/A, A/C, and C/C genotypes in the -98 promoter position were in Hardy-Weinberg equilibrium in the control but not in the PE group (p < 0.036). The dominant A/A genotype had higher frequency in the PE group (p < 0.001). The A/C and C/C genotypes protected from PE (p < 0.032). The ORs to develop term and all PE, calculated for the A/A genotype, previous PE, body mass index (BMI) >35, black ethnicity, and maternal age >40 were 15.6 and 11.0, respectively (p < 0.001). In luciferase assays, the "-98A" promoter variant had lower expression than the "-98C" variant in non-differentiated (-13%, p = 0.04) and differentiated (-26%, p < 0.001) BeWo cells. Forskolin-induced differentiation led to a larger expression increase in the "-98C" variant than in the "-98A" variant (4.55-fold vs. 3.85-fold, p < 0.001). CONCLUSION:Lower LGALS13 (PP13) expression with the "A" nucleotide in the -98 promoter region position (compared to "C") and high OR calculated for the A/A genotype in the -98A/C promoter region position, history of previous PE, BMI >35, advanced maternal age >40, and black ethnicity could serve to aid in PE prediction in the first trimester.

SUBMITTER: Madar-Shapiro L 

PROVIDER: S-EPMC5882584 | biostudies-other | 2018

REPOSITORIES: biostudies-other

altmetric image

Publications

Predicting the Risk to Develop Preeclampsia in the First Trimester Combining Promoter Variant -98A/C of LGALS13 (Placental Protein 13), Black Ethnicity, Previous Preeclampsia, Obesity, and Maternal Age.

Madar-Shapiro Liora L   Karady Ido I   Trahtenherts Alla A   Syngelaki Argryo A   Akolekar Ranjit R   Poon Liona L   Cohen Ruth R   Sharabi-Nov Adi A   Huppertz Berthold B   Sammar Marei M   Juhasz Kata K   Than Nandor Gabor NG   Papp Zoltan Z   Romero Roberto R   Nicolaides Kypros H KH   Meiri Hamutal H  

Fetal diagnosis and therapy 20170721 4


<h4>Background</h4>LGALS13 (placental protein 13 [PP13]) promoter DNA polymorphisms was evaluated in predicting preeclampsia (PE), given PP13's effects on hypotension, angiogenesis, and immune tolerance.<h4>Methods</h4>First-trimester plasma samples (49 term and 18 intermediate) of PE cases matched with 196 controls were collected from King's College Hospital, London, repository. Cell-free DNA was extracted and the LGALS13 exons were sequenced after PCR amplification. Expression of LGALS13 promo  ...[more]

Similar Datasets

| S-EPMC6047241 | biostudies-literature
| S-EPMC2667803 | biostudies-literature
| S-EPMC3598011 | biostudies-literature
| S-EPMC4013914 | biostudies-literature
| S-EPMC8289780 | biostudies-literature
| S-EPMC4596497 | biostudies-literature
| S-BSST753 | biostudies-other
2020-10-14 | GSE128827 | GEO